Mihaylova Anita S, Kostadinov Ilia D, Doncheva Nina D, Zlatanova Hristina I, Delev Delian P
Department of Pharmacology and Drug Toxicology, Faculty of Pharmacy, Medical University of Plovdiv, Plovdiv, Bulgaria.
Department of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria.
Folia Med (Plovdiv). 2019 Jun 1;61(2):258-265. doi: 10.2478/folmed-2018-0063.
Parkinson's disease (PD) is the second most common neurode-generative disease, usually detected by its motor symptoms. The non-motor symptoms, including cognitive deficits, have been of great interest to researchers in the last few decades.
To assess the effect of pramipexole on learning and memory in naïve and haloperidol-challenged rats.
Male Wistar rats divided into 9 groups (n=8): naïve - saline, pramipexole 0.5; 1 and 3 mg/kg bw; Haloperidol groups - saline, haloperidol, haloperidol + pramipexole 0.5; 1 and 3 mg/kg bw. Two-way active avoidance test (TWAA) and activity cage were performed. The studied parameters were: number of conditioned and unconditioned responses, vertical and horizontal movements. Statistical analysis was done using SPSS 19.
The naïve experimental groups significantly increased the number of conditioned responses during the tests for short- and long-term memory, compared with the saline groups (p<0.05). During the short-memory test only the animals with the lowest dose of PMX significantly increased the number of unconditioned responses whereas during the long-term memory test all experimental groups increased the number of escapes in comparison with the saline groups (p<0.05). Challenge dose of haloperidol attenuates learning and memory in pramipexol treated rats. Only the highest dose of pramipexol showed significant increase in conditioned and unconditioned responses compared with the haloperidol group (p<0.05).
Pramipexole improves learning and memory in naïve rats by enhancing dopaminergic neurotransmission. This is probably not the only mechanism involved. This is confirmed by the decrease in learning and memory ability in rats with haloperidol-challenge.
帕金森病(PD)是第二常见的神经退行性疾病,通常通过其运动症状来检测。在过去几十年中,包括认知缺陷在内的非运动症状一直是研究人员非常感兴趣的领域。
评估普拉克索对未用药和氟哌啶醇激发的大鼠学习和记忆的影响。
将雄性Wistar大鼠分为9组(n = 8):未用药 - 生理盐水组、普拉克索0.5;1和3mg/kg体重组;氟哌啶醇组 - 生理盐水组、氟哌啶醇组、氟哌啶醇 + 普拉克索0.5;1和3mg/kg体重组。进行双向主动回避试验(TWAA)和活动笼试验。研究的参数包括:条件反射和非条件反射的次数、垂直和水平运动。使用SPSS 19进行统计分析。
与生理盐水组相比,未用药的实验组在短期和长期记忆测试中条件反射次数显著增加(p<0.05)。在短期记忆测试中,只有最低剂量普拉克索组的动物非条件反射次数显著增加,而在长期记忆测试中,与生理盐水组相比,所有实验组的逃避次数均增加(p<0.05)。氟哌啶醇激发剂量会减弱普拉克索治疗大鼠的学习和记忆能力。与氟哌啶醇组相比,只有最高剂量的普拉克索显示条件反射和非条件反射次数显著增加(p<0.05)。
普拉克索通过增强多巴胺能神经传递改善未用药大鼠的学习和记忆。这可能不是唯一涉及的机制。氟哌啶醇激发大鼠学习和记忆能力下降证实了这一点。